uniQure (QURE) Misses Q3 EPS by 3c

Go back to uniQure (QURE) Misses Q3 EPS by 3c

uniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies

December 1, 2015 9:49 AM EST

Jefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More

uniQure BV (QURE) Sell-Off 'Unfounded' - Oppenheimer

December 1, 2015 7:11 AM EST

Oppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.

uniQure reported 3Q15, ending the quarter with $215M in cash.

Marai commented, "Importantly, QURE clarified the... More

uniQure BV (QURE) Ph1/2 MPS3b Has Strong Reception at ICSS - Cowen

November 30, 2015 7:44 AM EST

Cowen analyst Ritu Baral reiterated an Outperform rating on uniQure BV (NASDAQ: QURE) Ph1/2 12 mo. MPS3b AMT-110 data was presented again at ICSS Friday and was very well received by MPS3 KOLs.

Baral commented, "The trial PI noted 18 more mos. of... More